Comparison of Outcomes Between Warshaw and Kimura Techniques for Spleen-preserving Minimally Invasive Distal Pancreatectomy
1 other identifier
observational
314
1 country
1
Brief Summary
Spleen-persevering distal pancreatectomy (SP-DP) has been widely advocated as a routine procedure for benign or low-grade malignant tumors in the pancreatic body and tail, especially with a minimally invasive approach. Spleen preservation can be accomplished with Kimura technique (KT) or Warshaw technique (WT) Both of the two techniques were proved to be feasible and efficient. However, the perioperative outcomes and long-term benefits between patients with KT and WT in spleen-persevering minimally invasive distal pancreatectomy (SP-MIDP) remains controversial. Several small series have reported a slightly higher prevalence of postpancreatectomy hemorrhage (PPH) in patients who undergo KT than those undergo WT. The exposure of splenic vessels to erosive pancreatic juice and the preservation of splenic vessels itself may explain the higher chance of PPH in KT. Larger volume studies are warranted to confirm this finding and to clarify the clinical significance. This study compared the perioperative outcomes between the two spleen-preserving techniques, with a focus on parameters relating to perioperative patient safety. Especially, the incidence and clinical relevance of PPH in SP-MIDP were evaluated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedFirst Submitted
Initial submission to the registry
October 10, 2023
CompletedFirst Posted
Study publicly available on registry
October 16, 2023
CompletedOctober 16, 2023
October 1, 2023
4.5 years
October 10, 2023
October 10, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
major complications
(Clavien-Dindo grade ≥ III)
Within 30 days of SP-MIDP
Study Arms (2)
Kimura technique (KT)
Spleen preservation is accomplished by sparing the splenic vessels.
Warshaw technique (WT)
Spleen preservation is accomplished by sacrificing the splenic vessels and maintaining vascularity through the preserved short gastric and left gastroepiploic vessels.
Interventions
Eligibility Criteria
Patients who underwent SP-MIDP at our institution between July 2018 and December 2022 were enrolled consecutively.
You may qualify if:
- pathological diagnosis of benign or low-grade malignant pancreas tumors.
You may not qualify if:
- incomplete medical records,
- history of previous splenectomy,
- high-grade malignant pancreas tumors,
- conversion to open DP (ODP).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Biospecimen
Samples Without DNA
Study Officials
- PRINCIPAL INVESTIGATOR
Liang Tingbo
Zhejiang University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
October 10, 2023
First Posted
October 16, 2023
Study Start
July 1, 2018
Primary Completion
December 31, 2022
Study Completion
December 31, 2022
Last Updated
October 16, 2023
Record last verified: 2023-10